Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
4.6
Journals
Pharmaceuticals
Special Issues
PSMA Targeted Imaging and Radiation Therapy
share announcement

PSMA Targeted Imaging and Radiation Therapy

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Radiopharmaceutical Sciences".

Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 7618

Special Issue Editors

Dr. David Kryza

E-Mail Website
Guest Editor
Hospices civils de Lyon, Laboratoire d’Automatique, de Génie des Procédés et de Génie(LAGEPP), Université Claude Bernanrd Lyon1, Villeurbanne, France
Interests: cancer; theranostics; Mabs; nanoparticles; radiopharmaceuticals
Dr. Anne Laure Giraudet

E-Mail Website
Guest Editor
The Nuclear Medicine Department, Centre Léon Bérard, Lyon, France
Interests: cancer; theranostics; PET; SPECT

Special Issue Information

Dear Colleagues,

Prostate-specific membrane antigen (PSMA) is highly expressed on the membrane of most prostate cancer cells and in many other cells, such as renal proximal tubular epithelium and duodenum columnar epithelium. PSMA is also expressed in the endothelium of tumor-associated neovasculature. Many radiopharmaceuticals have been developed to target this protein, and numerous clinical studies have demonstrated that PSMA imaging has shown promise result in evaluating treatment response in hormone-sensitive and castration-resistant disease. Furthermore, encouraging results have been observed from PSMA-based theranostics in prostate cancer tumors now available in nuclear medicine department. However, we should continue to intensify preclinical and clinical research on radiopharmaceutical targeting PSMA.

This Special Issue of Pharmaceuticals welcomes articles (original research, review, and short communication) on the production and (pre)clinical use of radiopharmaceutical targeting PSMA for cancer imaging and/or therapy.

Dr. David Kryza
Dr. Anne Laure Giraudet
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • PSMA imaging
  • radionuclide therapy
  • clinical trial
  • innovative radionuclide
  • Mabs
  • peptide theranostics

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

19 pages, 10560 KiB  
Article
Characterization of Non-Specific Uptake and Retention Mechanisms of [177Lu]Lu-PSMA-617 in the Salivary Glands
by Nathalie Heynickx, Charlotte Segers, Amelie Coolkens, Sarah Baatout and Koen Vermeulen
Pharmaceuticals 2023, 16(5), 692; https://doi.org/10.3390/ph16050692 - 03 May 2023
Cited by 5 | Viewed by 2026
Abstract
The radionuclide therapy [177Lu]Lu-PSMA-617 was recently FDA-approved for treatment of metastatic castration-resistant prostate cancer. Salivary gland toxicity is currently considered as the main dose-limiting side effect. However, its uptake and retention mechanisms in the salivary glands remain elusive. Therefore, our aim [...] Read more.
The radionuclide therapy [177Lu]Lu-PSMA-617 was recently FDA-approved for treatment of metastatic castration-resistant prostate cancer. Salivary gland toxicity is currently considered as the main dose-limiting side effect. However, its uptake and retention mechanisms in the salivary glands remain elusive. Therefore, our aim was to elucidate the uptake patterns of [177Lu]Lu-PSMA-617 in salivary gland tissue and cells by conducting cellular binding and autoradiography experiments. Briefly, A-253 and PC3-PIP cells, and mouse kidney and pig salivary gland tissue, were incubated with 5 nM [177Lu]Lu-PSMA-617 to characterize its binding. Additionally, [177Lu]Lu-PSMA-617 was co-incubated with monosodium glutamate, ionotropic or metabotropic glutamate receptor antagonists. Low, non-specific binding was observed in salivary gland cells and tissues. Monosodium glutamate was able to decrease [177Lu]Lu-PSMA-617 in PC3-PIP cells, mouse kidney and pig salivary gland tissue. Kynurenic acid (ionotropic antagonist) decreased the binding of [177Lu]Lu-PSMA-617 to 29.2 ± 20.6% and 63.4 ± 15.4%, respectively, with similar effects observed on tissues. (RS)-MCPG (metabotropic antagonist) was able to decrease the [177Lu]Lu-PSMA-617 binding on A-253 cells to 68.2 ± 16.8% and pig salivary gland tissue to 53.1 ± 36.8%. To conclude, we showed that the non-specific binding on [177Lu]Lu-PSMA-617 could be reduced by monosodium glutamate, kynurenic acid and (RS)-MCPG. Full article
(This article belongs to the Special Issue PSMA Targeted Imaging and Radiation Therapy)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

11 pages, 807 KiB  
Review
Rationale for Prostate-Specific-Membrane-Antigen-Targeted Radionuclide Theranostic Applied to Metastatic Clear Cell Renal Carcinoma
by Anne Laure Giraudet, Armelle Vinceneux, Valentin Pretet, Emilie Paquet, Alicia Sanchez Lajusticia, Fouzi Khayi, Jean Noël Badel, Helen Boyle, Aude Flechon and David Kryza
Pharmaceuticals 2023, 16(7), 995; https://doi.org/10.3390/ph16070995 - 12 Jul 2023
Cited by 1 | Viewed by 1644
Abstract
Prostate-specific membrane antigen (PSMA), whose high expression has been demonstrated in metastatic aggressive prostate adenocarcinoma, is also highly expressed in the neovessels of various solid tumors, including clear cell renal cell carcinoma (ccRCC). In the VISION phase III clinical trial, PSMA-targeted radioligand therapy [...] Read more.
Prostate-specific membrane antigen (PSMA), whose high expression has been demonstrated in metastatic aggressive prostate adenocarcinoma, is also highly expressed in the neovessels of various solid tumors, including clear cell renal cell carcinoma (ccRCC). In the VISION phase III clinical trial, PSMA-targeted radioligand therapy (PRLT) with lutetium 177 demonstrated a 4-month overall survival OS benefit compared to the best standard of care in heavily pretreated metastatic prostate cancer. Despite the improvement in the management of metastatic clear cell renal cell carcinoma (mccRCC) with antiangiogenic tyrosine kinase inhibitor (TKI) and immunotherapy, there is still a need for new treatments for patients who progress despite these drugs. In this study, we discuss the rationale of PRLT applied to the treavtment of mccRCC. Full article
(This article belongs to the Special Issue PSMA Targeted Imaging and Radiation Therapy)
►▼ Show Figures

Figure 1

12 pages, 1128 KiB  
Review
RadioLigand Therapy with [177Lu]Lu-PSMA-617 for Salivary Gland Cancers: Literature Review and First Compassionate Use in France
by Marie Terroir, Chloé Lamesa, Mehdi Krim, Lavinia Vija, Jean-Sébastien Texier, Thibaut Cassou-Mounat, Jean-Pierre Delord, Delphine Vallot and Frédéric Courbon
Pharmaceuticals 2023, 16(5), 754; https://doi.org/10.3390/ph16050754 - 16 May 2023
Cited by 3 | Viewed by 1582
Abstract
Salivary gland cancers are rare tumors comprising a large group of heterogeneous tumors with variable prognosis. Their therapeutic management at a metastatic stage is challenging due to the lack of therapeutic lines and the toxicity of treatments. [177Lu]Lu-PSMA-617 (prostate-specific membrane antigen) [...] Read more.
Salivary gland cancers are rare tumors comprising a large group of heterogeneous tumors with variable prognosis. Their therapeutic management at a metastatic stage is challenging due to the lack of therapeutic lines and the toxicity of treatments. [177Lu]Lu-PSMA-617 (prostate-specific membrane antigen) is a vectored radioligand therapy (RLT) initially developed to treat castration-resistant metastatic prostate cancer with encouraging results in terms of efficacy and toxicity. Many malignant cells could be treated with [177Lu]Lu-PSMA-617 as long as they express PSMA as a consequence of androgenic pathway activation. RLT may be used when anti-androgen hormonal treatment has failed, particularly in prostate cancer. [177Lu]Lu-PSMA-617 has been proposed in certain salivary gland cancers, though the expression of PSMA is demonstrated by a significant uptake using [68Ga]Ga-PSMA-11 PET scan. This theranostic approach could be a new therapeutic option, warranting prospective investigation in a larger cohort. We review the literature on this subject and offer a clinical illustration of compassionate use in France as a perspective for administering [177Lu]Lu-PSMA-617 in salivary gland cancer. Full article
(This article belongs to the Special Issue PSMA Targeted Imaging and Radiation Therapy)
►▼ Show Figures

Figure 1

16 pages, 1774 KiB  
Review
Can PSMA-Targeting Radiopharmaceuticals Be Useful for Detecting Hepatocellular Carcinoma Using Positron Emission Tomography? An Updated Systematic Review and Meta-Analysis
by Alessio Rizzo, Manuela Racca, Domenico Albano, Francesco Dondi, Francesco Bertagna, Salvatore Annunziata and Giorgio Treglia
Pharmaceuticals 2022, 15(11), 1368; https://doi.org/10.3390/ph15111368 - 08 Nov 2022
Cited by 6 | Viewed by 1775
Abstract
Background: Several studies proposed the use of positron emission tomography (PET) with Prostate-Specific Membrane Antigen (PSMA)-targeting radiopharmaceuticals in hepatocellular carcinoma (HCC). Our aim is to calculate the detection rate (DR) of this examination in HCC with a meta-analysis. Methods: A comprehensive literature search [...] Read more.
Background: Several studies proposed the use of positron emission tomography (PET) with Prostate-Specific Membrane Antigen (PSMA)-targeting radiopharmaceuticals in hepatocellular carcinoma (HCC). Our aim is to calculate the detection rate (DR) of this examination in HCC with a meta-analysis. Methods: A comprehensive literature search of studies on the DR of PET/CT or PET/MRI with PSMA-targeting radiopharmaceuticals in HCC was performed. Original articles evaluating these imaging examinations both in newly diagnosed HCC patients and HCC patients with disease relapse were included. Pooled DR including 95% confidence intervals (95% CI) was calculated. Statistical heterogeneity was also assessed using the I2 test. Results: The meta-analysis of six selected studies (126 patients) provided a DR of 85.9% for PET imaging with PSMA-targeting radiopharmaceuticals in the diagnosis of HCC. Moderate statistical heterogeneity among the included studies was found (I2 = 56%). Conclusions: The quantitative data provided demonstrate the high DR of PET/CT or PET/MRI with PSMA-targeting radiopharmaceuticals for HCC lesion detection. However, more studies are needed to confirm the promising role of PSMA-targeted PET in HCC. Full article
(This article belongs to the Special Issue PSMA Targeted Imaging and Radiation Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop